Journals / Annals of Medical Research / 2019 / Cilt: 26 - Sayı: 5

Chemotherapeutic effects of doxorubicin loaded PEG coated TiO􀐁 nanocarriers on breast cancer cell lines

Pages
821–826
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Apoptosis and necrosis were determined byfluorescence microscopy using the Hoechst 33258 (HO) /propidium iodide (PI) double staining.Results: The effects of TiO􀐁, PEG-TiO􀐁, DOX, and TiO􀐁-PEG-DOX on the MDA-MB-231 cell line were compared with the control groupand IC50 values were determined for 24, 48 and 72 hours.Conclusion: In this study, it was shown that the effect of TiO􀐁-PEG-DOX nanostructured system on MDA-MB-231 cell line wasinhibition growth in cancer cells and induction of apoptosis when compared with control group and DOX.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Breast cancer is the most common frequently diagnosed malignancy among women and leading cause of cancer death inwomen worldwide.
📊
Key Findings & Data:The aim of this study is 1) to increase the biocompatibility of the titanium dioxide (TiO􀐁) nanoparticles (NPs)by coating it with PolyEthylene Glycol (PEG) and to develop a new nanostructure system and 2) to determine anticancer activity ofdoxorubicin (DOX) loaded PEG-TiO􀐁 on MDA-MB-231 cell lines.Material and Methods: TiO􀐁 nanoparticles used in this study were synthesized, coated with PEG, and PEG-TiO􀐁 nanostructure systemwas loaded by DOX.
💡
Conclusion & Impact:Apoptosis and necrosis were determined byfluorescence microscopy using the Hoechst 33258 (HO) /propidium iodide (PI) double staining.Results: The effects of TiO􀐁, PEG-TiO􀐁, DOX, and TiO􀐁-PEG-DOX on the MDA-MB-231 cell line were compared with the control groupand IC50 values were determined for 24, 48 and 72 hours.Conclusion: In this study, it was shown that the effect of TiO􀐁-PEG-DOX nanostructured system on MDA-MB-231 cell line wasinhibition growth in cancer cells and induction of apoptosis when compared with control group and DOX.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Breast cancer is the most common frequently diagnosed malignancy among women and leading cause of cancer death inwomen worldwide. The aim of this study is 1) to increase the biocompatibility of the titanium dioxide (TiO􀐁) nanoparticles (NPs)by coating it with PolyEthylene Glycol (PEG) and to develop a new nanostructure system and 2) to determine anticancer activity ofdoxorubicin (DOX) loaded PEG-TiO􀐁 on MDA-MB-231 cell lines.Material and Methods: TiO􀐁 nanoparticles used in this study were synthesized, coated with PEG, and PEG-TiO􀐁 nanostructure systemwas loaded by DOX. UV analysis was performed on the prepared solutions. The synthesized drugs were applied to the MDA-MB-231breast cancer cell line and cytotoxic effect of these drugs were determined by using MTT method. The MDA-MB-231 cells weretreated with different concentrations of TiO􀐁 (5-100 μg/ml) for 24, 48 and 72 hours. Apoptosis and necrosis were determined byfluorescence microscopy using the Hoechst 33258 (HO) /propidium iodide (PI) double staining.Results: The effects of TiO􀐁, PEG-TiO􀐁, DOX, and TiO􀐁-PEG-DOX on the MDA-MB-231 cell line were compared with the control groupand IC50 values were determined for 24, 48 and 72 hours.Conclusion: In this study, it was shown that the effect of TiO􀐁-PEG-DOX nanostructured system on MDA-MB-231 cell line wasinhibition growth in cancer cells and induction of apoptosis when compared with control group and DOX.

🔖

Cite This Article

GUMUS, E., TAS, A., SİLİG, Y., ÇAKMAK, N. K., ATABEY, M. (2022). Chemotherapeutic effects of doxorubicin loaded PEG coated TiO􀐁 nanocarriers on breast cancer cell lines. Annals of Medical Research, Cilt: 26 - Sayı: 5, 821–826. https://ajindex.com/articles/446822

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: a cancer journal for clinicians 2011;61:69-90
  2. Marsh S, McLeod HL. Pharmacogenetics and oncology treatment for breast cancer. Expert opinion on pharmacotherapy 2007;8:119-27
  3. Youlden DR, Cramb SM, Dunn NA, et al. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer epidemiology 2012;36:237-48
  4. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009;86:215-23
  5. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr opin oncol 2000;12:450- 8
  6. Mayer LD, Shabbits JA. The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Cancer Metastasis Rev 2001;20:87- 93
  7. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008;34:378-90
  8. Schöndorf T, Kurbacher CM, Göhring UJ, et al. Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res 2002;22:2199-203
  9. Linn SC, Giaccone G. Mdr1/P-Glycoprotein expression in colorectal-cancer. Eur J Cancer 1995;31:1291-4
  10. Yu ST, Chen TM, Tseng SY, et al. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Comm 2007;358:79-84
  11. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229
  12. Patil RR, Guhagarkar SA, Devarajan PV. Engineered nanocarriers of doxorubicin: a current update. Crit Rev Ther Drug Carrier Syst 2008;25:1-61
  13. Peer D, Karp J M, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751- 60
  14. Jabr-Milane LS, van Vlerken LE, Yadav S, et al. Multifunctional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008;34:592-602
  15. Cho K, Wang XU, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310-6
  16. Venkatasubbu D, Ramasamy S, Ramakrishnan V, et al. Folate targeted PEGylated titanium dioxide nanoparticles as a nanocarrier for targeted paclitaxel drug delivery. Advan Powder Technol 2013;24:947-54
  17. Chen Y, Wan Y, Wang Y, et al. Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxid